Anicura-Lorrainevet, Ludres, France.
Advetia, Vélizy Villacoublay, France.
J Feline Med Surg. 2024 Feb;26(2):1098612X231220848. doi: 10.1177/1098612X231220848.
The aim of the study was to assess long-term ciclosporin oral solution compliance in cats treated for feline atopic skin syndrome (FASS).
A survey was sent by email to 114 owners who had administered ciclosporin oral solution to their cats for FASS.
In total, 42 owners completed the survey. The population was composed of 30 domestic shorthair cats and 12 pure breeds. There were 20 males and 22 females, and the median age was 5.5 years. Ciclosporin oral solution was administered directly into the mouth in 32/42 (76%) and with food/other in 10/42 (24%) cats. The administration was considered easy in 18/42 (43%) cats, difficult in 23/42 (55%) and impossible in 1/42 (2%). Treatment was stopped in 25/42 (60%) cats. The causes were as follows: administration difficulty (nine cats, 21%); complete resolution (four cats, 10%); treatment failure (four cats, 10%); price (two cats, 4%); and other causes (two deaths, two neoplasia, one adverse effect and one lack of compliance). Adverse effects involving clinical signs were reported in 25 (60%) cats: ptyalism (8/42); dysorexia/anorexia (6/42); vomiting (4/42); diarrhoea (4/42); gingival hyperplasia (1/42); and a combination of vomiting, diarrhoea and ptyalism (2/42). In addition, altered behaviour was reported in 27/42 (64%) cats: hiding in seven cats; scared of owner in 10 cats; modification of sleeping or playing activity in six cats; inappropriate urination/defecation in two cats; aggression in one cat; and all of the above in one cat.
In total, 24 (57%) cats had adverse effects involving both clinical signs and altered behaviour, and only six cats had either adverse clinical signs or behavioural changes. This survey showed that behavioural changes appear to be underestimated in the cats treated with ciclosporin oral solution and this could cause treatment failure due to lack of compliance. Larger-scale studies are needed to confirm these preliminary results.
本研究旨在评估接受环孢素口服液治疗猫特应性皮炎综合征(FASS)的猫的长期环孢素口服液依从性。
通过电子邮件向 114 名曾为其猫使用环孢素口服液治疗 FASS 的猫主人发送了一份调查问卷。
共有 42 位猫主人完成了调查。该人群由 30 只家短毛猫和 12 只纯种猫组成。有 20 只雄性和 22 只雌性,中位年龄为 5.5 岁。32/42(76%)只猫直接将环孢素口服液喂入口腔,10/42(24%)只猫将环孢素口服液混入食物/其他物品中喂食。18/42(43%)只猫认为给药容易,23/42(55%)只猫认为给药困难,1/42(2%)只猫认为给药不可能。25/42(60%)只猫停止了治疗。原因如下:给药困难(9 只猫,21%);完全缓解(4 只猫,10%);治疗失败(4 只猫,10%);价格(2 只猫,4%);以及其他原因(2 只死亡,2 只肿瘤,1 只不良反应,1 只不依从)。25(60%)只猫出现了涉及临床症状的不良反应:流涎(8/42);食欲不振/厌食(6/42);呕吐(4/42);腹泻(4/42);牙龈增生(1/42);呕吐、腹泻和流涎的组合(2/42)。此外,27/42(64%)只猫出现了改变的行为:7 只猫躲藏;10 只猫害怕主人;6 只猫改变了睡眠或玩耍活动;2 只猫出现不适当的排尿/排便;1 只猫出现攻击行为;1 只猫出现上述所有行为。
总的来说,24(57%)只猫出现了涉及临床症状和行为改变的不良反应,只有 6 只猫出现了临床症状或行为改变中的任何一种。本研究表明,接受环孢素口服液治疗的猫的行为改变似乎被低估了,这可能导致因不依从而治疗失败。需要更大规模的研究来证实这些初步结果。